Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

XOMA

XOMA Royalty Corp

Dec 13 • 04:00PM ET

27.15

Dollar change -0.88
Percentage change -3.14	%

Healthcare • Biotechnology • USA • NASD

Peers: AMGN GILD VRTX REGN BMRN BIIB IONS INCY NBIX EXEL

| Held by: VTI IWM VXF IWO VTWO IWN IWC VTWG RSSL DFAC

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-3.48	Insider Own	0.86%	Shs Outstand	11.76M	Perf Week	-9.95%
Market Cap	309.86M	Forward P/E	-	EPS next Y	-0.55	Insider Trans	-23.80%	Shs Float	11.68M	Perf Month	-8.62%
Income	-39.83M	PEG	-	EPS next Q	-0.29	Inst Own	65.41%	Short Float	0.96%	Perf Quarter	-5.07%
Sales	21.61M	P/S	14.34	EPS this Y	73.27%	Inst Trans	0.30%	Short Ratio	4.08	Perf Half Y	7.40%
Book/sh	7.21	P/B	3.77	EPS next Y	49.07%	ROA	-17.25%	Short Interest	0.11M	Perf Year	69.79%
Cash/sh	12.52	P/C	2.17	EPS next 5Y	19.00%	ROE	-31.41%	52W Range	14.89 - 35.00	Perf YTD	46.76%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-20.43%	ROI	-20.58%	52W High	-22.43%	Beta	0.88
Dividend TTM	-	Quick Ratio	7.52	Sales past 5Y	46.25%	Gross Margin	98.92%	52W Low	82.34%	ATR (14)	1.44
Dividend Ex-Date	-	Current Ratio	7.52	EPS Y/Y TTM	-22.66%	Oper. Margin	-71.30%	RSI (14)	32.81	Volatility	4.04% 4.66%
Employees	13	Debt/Eq	1.40	Sales Y/Y TTM	389.82%	Profit Margin	-184.33%	Recom	1.67	Target Price	89.00
Option/Short	Yes / Yes	LT Debt/Eq	1.28	EPS Q/Q	-165.10%	Payout	-	Rel Volume	0.89	Prev Close	28.03
Sales Surprise	10.61%	EPS Surprise	-264.09%	Sales Q/Q	767.11%	Earnings	Nov 07 BMO	Avg Volume	27.56K	Price	27.15
SMA20	-11.36%	SMA50	-9.30%	SMA200	0.85%	Trades		Volume	24,553	Change	-3.14%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-29-24	Initiated	Leerink Partners	Outperform	$40
Sep-07-21	Downgrade	Wedbush	Outperform → Neutral	$22
Jun-29-21	Initiated	Aegis Capital	Buy	$60
Jan-19-21	Reiterated	H.C. Wainwright	Buy	$30 → $56
Jan-18-18	Reiterated	H.C. Wainwright	Buy	$38 → $49
Oct-17-17	Resumed	H.C. Wainwright	Buy	$38
Sep-05-17	Upgrade	Wedbush	Neutral → Outperform	$9 → $19
Jun-12-17	Initiated	H.C. Wainwright	Buy	$15
Nov-14-16	Downgrade	Wedbush	Outperform → Neutral	$17 → $14
Mar-11-16	Reiterated	Wedbush	Outperform	$6 → $3
Jul-23-15	Downgrade	Jefferies	Buy → Hold
Jul-22-15	Downgrade	Piper Jaffray	Overweight → Neutral
Jul-22-15	Downgrade	Ladenburg Thalmann	Buy → Neutral
Oct-10-14	Resumed	ROTH Capital	Buy	$9
Apr-29-14	Upgrade	MLV & Co	Hold → Buy	$7
Mar-11-14	Downgrade	MLV & Co	Buy → Hold	$8 → $7
Mar-05-14	Reiterated	Ladenburg Thalmann	Buy	$6.50 → $10
Oct-31-13	Reiterated	MLV & Co	Buy	$7.50 → $8
May-09-13	Reiterated	Ladenburg Thalmann	Buy	$5 → $6
May-14-12	Initiated	Cowen & Co	Outperform

Show Previous Ratings

Dec-02-24 07:30AM	XOMA Royalty Acquires Pulmokine for $20 Million Adding the Royalty and Milestone Interest in Seralutinib, a Phase 3 Asset, to Its Portfolio (GlobeNewswire)
Nov-11-24 12:00PM	What Makes XOMA Royalty (XOMA) a New Buy Stock (Zacks)
Nov-07-24 09:00AM	XOMA Royalty (XOMA) Reports Q3 Loss, Tops Revenue Estimates (Zacks) -6.96%
07:52AM	XOMA Royalty: Q3 Earnings Snapshot (Associated Press Finance)
07:30AM	XOMA Royalty Reports Third Quarter 2024 Financial Results and Highlights Recent Activities (GlobeNewswire)
08:00AM	Loading…
Oct-22-24 08:00AM	XOMA Royalty Significantly Expands its Royalty and Milestone Portfolio with the Addition of Over 60 Early-Stage Programs from Twist Bioscience (GlobeNewswire)
08:00AM	Twist Bioscience Enters into Royalty Purchase Agreement with XOMA Royalty for $15 Million in Cash (Business Wire)
Sep-23-24 06:30AM	Zevra's MIPLYFFA (arimoclomol) Receives Approval from U.S. Food and Drug Administration for Use in Patients with Niemann-Pick Disease Type C (NPC) (GlobeNewswire)
05:30AM	XOMA Royalty Declares Quarterly Preferred Stock Dividends (GlobeNewswire)
Sep-04-24 07:30AM	XOMA Royalty to Present at Upcoming Investor Conferences in September (GlobeNewswire)
Aug-13-24 08:45AM	XOMA Royalty (XOMA) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +14.40%
07:39AM	XOMA Royalty: Q2 Earnings Snapshot (Associated Press Finance)
07:30AM	XOMA Royalty Reports Second Quarter 2024 Financial Results and Highlights Recent Activities (GlobeNewswire)
Jul-18-24 04:08AM	Xoma (XOMA) Surges 6.4%: Is This an Indication of Further Gains? (Zacks)
Jun-21-24 07:54AM	Xoma (XOMA) Soars 15.6%: Is Further Upside Left in the Stock? (Zacks) -5.23%
07:30AM	Loading…
Jun-20-24 07:30AM	XOMA Declares Quarterly Preferred Stock Dividends (GlobeNewswire) +15.64%
Jun-12-24 07:30AM	XOMA Receives $8.1 Million Milestone Related to Day One Biopharmaceuticals' Sale of its Priority Review Voucher (GlobeNewswire)
06:00AM	3 Crazy Good Stocks to Buy With $500 Right Now (InvestorPlace)
May-14-24 07:30AM	XOMA to Present at H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQ (GlobeNewswire)
May-10-24 03:18PM	XOMA Corp (XOMA) Q1 2024 Earnings: Misses Revenue Estimates, Reports Lower Net Loss (GuruFocus.com) +7.39%
May-09-24 01:55PM	XOMA Stock Earnings: XOMA Misses EPS, Beats Revenue for Q1 2024 (InvestorPlace)
08:00AM	Xoma: Q1 Earnings Snapshot (Associated Press Finance)
07:30AM	XOMA Reports First Quarter 2024 Financial Results and Highlights Recent Activities (GlobeNewswire)
May-07-24 10:00AM	Xoma (XOMA) May Report Negative Earnings: Know the Trend Ahead of Q1 Release (Zacks)
Apr-30-24 07:30AM	XOMA Adds Economic Interests in Three First-in-Category Assets to its Royalty and Milestone Portfolio Including XACIATO (clindamycin phosphate) Vaginal Gel 2% (GlobeNewswire)
Apr-25-24 07:30AM	XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One's OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG) (GlobeNewswire)
Apr-24-24 09:00AM	Actym Therapeutics Appoints Thomas Smart as CEO (PR Newswire)
Apr-03-24 09:00AM	XOMA Corporation Announces Closing of Tender Offer (GlobeNewswire)
Mar-21-24 07:30AM	XOMA Declares Quarterly Preferred Stock Dividends (GlobeNewswire)
Mar-19-24 04:05PM	XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc. (GlobeNewswire)
12:53PM	Loading…
Mar-08-24 12:53PM	XOMA Stock Earnings: XOMA Misses EPS, Misses Revenue for Q4 2023 (InvestorPlace)
08:12AM	XOMA Corp (XOMA) Reports Mixed Financial Results for Q4 and Full Year 2023 (GuruFocus.com)
07:52AM	Xoma: Q4 Earnings Snapshot (Associated Press Finance)
07:30AM	XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Value (GlobeNewswire)
Feb-28-24 07:30AM	XOMA to Present at Upcoming Investor Conferences in March (GlobeNewswire)
Feb-16-24 08:00AM	XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right (GlobeNewswire)
Jan-18-24 08:30AM	XOMA Expands its Commercial Royalty and Milestone Portfolio with DSUVIA Acquisition (GlobeNewswire)
Jan-11-24 04:05PM	FDA Acceptance of Zevra's Arimoclomol NDA Filing for Niemann-Pick Disease Type C (NPC) Results in XOMA Making a $1 Million Milestone Payment to LadRx (GlobeNewswire)
Jan-08-24 07:30AM	XOMA Names Owen Hughes as Chief Executive Officer and Appoints Jack L. Wyszomierski as Chairman of the Board of Directors (GlobeNewswire)
Jan-02-24 07:30AM	XOMA Announces Stock Repurchase Program of up to $50 Million (GlobeNewswire) +12.92%
Dec-20-23 07:30AM	XOMA Declares Quarterly Preferred Stock Dividends (GlobeNewswire)
Dec-19-23 07:30AM	XOMA Raises up to $140 Million in Non-Dilutive, Non-Recourse Financing from Funds Managed by Blue Owl Capital Backed by VABYSMO Royalties (GlobeNewswire) +16.23%
Nov-07-23 07:50AM	Xoma: Q3 Earnings Snapshot (Associated Press Finance) -6.44%
07:30AM	XOMA Reports Third Quarter 2023 Financial Results and Highlights Upcoming Events Expected to Drive Shareholder Value (GlobeNewswire)
Oct-31-23 07:30AM	XOMA Earns $5 Million Milestone Upon FDA Acceptance of Day One's Tovorafenib NDA for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG) (GlobeNewswire) +5.66%
Sep-25-23 07:30AM	XOMA Declares Quarterly Preferred Stock Dividends (GlobeNewswire) -6.26%
Sep-06-23 07:30AM	XOMA to Present at H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-31-23 10:43PM	10 Stocks That Are About To Explode (Insider Monkey)
Aug-13-23 10:07AM	Owning 35% shares,institutional owners seem interested in XOMA Corporation (NASDAQ:XOMA), (Simply Wall St.)
Aug-08-23 08:21AM	Xoma: Q2 Earnings Snapshot (Associated Press Finance)
07:30AM	XOMA Reports Second Quarter 2023 Financial Results and Provides Update on its Royalty Monetization Strategy (GlobeNewswire)
Jun-23-23 06:14PM	XOMA Added to the Russell 2000® and Russell 3000® Indexes (GlobeNewswire)
Jun-22-23 07:30AM	XOMA Acquires Royalty and Milestone Economics to Phase 3 First-In-Class Orphan Disease Asset for Niemann-Pick Disease Type C (NPC) and Phase 2 Oncology Asset (GlobeNewswire)
Jun-20-23 07:30AM	XOMA Declares Quarterly Preferred Stock Dividends (GlobeNewswire) +9.30%
May-16-23 09:29AM	Shareholders in XOMA (NASDAQ:XOMA) are in the red if they invested five years ago (Simply Wall St.)
May-09-23 07:53AM	Xoma: Q1 Earnings Snapshot (AP Finance)
07:30AM	XOMA Reports First Quarter 2023 Financial Results and Provides Update on the Acceleration of its Differentiated Royalty Monetization Strategy (GlobeNewswire)
Apr-26-23 07:30AM	XOMA to Present at H.C. Wainwright BioConnect Investor Conference (GlobeNewswire) +5.61%
Mar-30-23 07:30AM	XOMA Acquires Cashflow-Generating Asset for its Royalty and Milestone Portfolio (GlobeNewswire)
Mar-21-23 07:30AM	XOMA Declares Quarterly Preferred Stock Dividends (GlobeNewswire)
Mar-10-23 05:36AM	XOMA Full Year 2022 Earnings: Revenues Beat Expectations, EPS In Line (Simply Wall St.)
Mar-09-23 07:50AM	Xoma: Q4 Earnings Snapshot (AP Finance) +5.76%
07:30AM	XOMA Reports Full-Year 2022 Financial Results and Provides Update to the Acceleration of its Differentiated Royalty Monetization Strategy (GlobeNewswire)
Mar-06-23 08:28AM	XOMA Corporation's (NASDAQ:XOMA) largest shareholders are individual investors with 37% ownership, hedge funds own 32% (Simply Wall St.)
Feb-28-23 07:30AM	XOMA to Present at 43rd Annual Cowen Health Care Conference (GlobeNewswire)
Jan-06-23 07:00PM	XOMA Announces New Employment Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -18.47%
Jan-04-23 07:30AM	New Executive Leadership Team Appointed to Accelerate XOMAs Differentiated Royalty Monetization Strategy (GlobeNewswire)
Dec-22-22 07:30AM	XOMA Declares Quarterly Preferred Stock Dividends (GlobeNewswire)
Dec-07-22 07:44AM	XOMA (NASDAQ:XOMA) shareholders have endured a 39% loss from investing in the stock five years ago (Simply Wall St.)
Nov-22-22 07:01AM	XOMA Acquires Royalty and Milestone License to Ebopiprant, a Preterm Labor Asset, Being Developed by Organon (GlobeNewswire) +15.91%
Nov-06-22 09:24AM	XOMA Corporation's (NASDAQ:XOMA) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong? (Simply Wall St.)
Nov-03-22 09:05AM	Xoma (XOMA) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
07:30AM	XOMA Reports Third Quarter 2022 Financial Results and Highlights Recent Operational Events (GlobeNewswire)
Sep-27-22 08:30AM	Hedge funds own 31% of XOMA Corporation (NASDAQ:XOMA) shares but individual investors control 40% of the company (Simply Wall St.)
Sep-21-22 07:30AM	XOMA Declares Quarterly Preferred Stock Dividends (GlobeNewswire)
Sep-07-22 07:30AM	XOMA to Present at H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire)
Sep-01-22 06:20AM	Is There An Opportunity With XOMA Corporation's (NASDAQ:XOMA) 49% Undervaluation? (Simply Wall St.) -7.34%
Aug-11-22 06:22AM	Time To Worry? Analysts Are Downgrading Their XOMA Corporation (NASDAQ:XOMA) Outlook (Simply Wall St.)
Aug-04-22 10:45AM	Xoma (XOMA) Reports Q2 Loss, Misses Revenue Estimates (Zacks) -6.64%
07:30AM	XOMA Reports Second Quarter 2022 Financial Results and Highlights Recent Operational Events (GlobeNewswire)
Jun-30-22 07:33AM	Investing in XOMA (NASDAQ:XOMA) five years ago would have delivered you a 196% gain (Simply Wall St.) +8.95%
Jun-20-22 07:30AM	XOMA Declares Quarterly Preferred Stock Dividends (GlobeNewswire)
Jun-02-22 01:00AM	Kuros Biosciences: Completion of the Acquisition of Checkmate Pharmaceuticals by Regeneron Pharmaceuticals Triggers a $5 Million Milestone Payment (GlobeNewswire)
May-30-22 07:06AM	Is Weakness In XOMA Corporation (NASDAQ:XOMA) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects? (Simply Wall St.)
May-17-22 04:05PM	XOMA to Present at H.C. Wainwright Global Investment Conference (GlobeNewswire)
May-07-22 08:27AM	This Just In: Analysts Are Boosting Their XOMA Corporation (NASDAQ:XOMA) Outlook for This Year (Simply Wall St.)
May-05-22 08:55AM	Xoma (XOMA) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
07:30AM	XOMA Reports First Quarter 2022 Financial Results and Highlights Recent Operational Events (GlobeNewswire)
May-03-22 08:15AM	Kymera Therapeutics, Inc. (KYMR) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
Apr-20-22 08:24AM	What Is The Ownership Structure Like For XOMA Corporation (NASDAQ:XOMA)? (Simply Wall St.)
Mar-21-22 07:30AM	XOMA Declares Quarterly Preferred Stock Dividends (GlobeNewswire)
Mar-15-22 06:21AM	XOMA Corporation's (NASDAQ:XOMA) 32% Share Price Surge Not Quite Adding Up (Simply Wall St.)
Mar-10-22 09:43AM	XOMA Corporation (NASDAQ:XOMA) Shares Could Be 20% Below Their Intrinsic Value Estimate (Simply Wall St.)
07:30AM	XOMA to Present at Oppenheimers 32nd Annual Healthcare Conference (GlobeNewswire)
Mar-08-22 07:30AM	XOMA Reports Full Year 2021 Financial Results and Highlights Recent Operational Events (GlobeNewswire) +11.47%
Mar-01-22 07:30AM	XOMA to Present at the 42nd Annual Cowen Health Care Conference (GlobeNewswire)
Feb-17-22 07:30AM	XOMA to Present at Aegis Capital Corp Investor Conference (GlobeNewswire)
Jan-21-22 10:21AM	XOMA's (NASDAQ:XOMA) investors will be pleased with their massive 368% return over the last five years (Simply Wall St.)
Dec-23-21 07:30AM	XOMA Declares Quarterly Preferred Stock Dividends (GlobeNewswire)
Dec-21-21 07:30AM	XOMA to Present at Upcoming Investor Conferences (GlobeNewswire) +7.94%

XOMA Royalty Corp. operates as a biotech royalty aggregator, which engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. The company focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners. It has a portfolio with various assets that provides right to future potential royalty and milestone payments. The company was founded by Patrick J. Scannon in 1981 and is headquartered in Emeryville, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
BURNS THOMAS M.	SVP, Finance & CFO	Nov 11 '24	Option Exercise	0.00	17,773	0	24,328	Nov 13 06:55 PM
BURNS THOMAS M.	SVP, Finance & CFO	Nov 13 '24	Sale	29.94	9,775	292,664	14,553	Nov 13 06:55 PM
Hughes Owen	Chief Executive Officer	Nov 11 '24	Option Exercise	0.00	53,360	0	56,860	Nov 13 06:55 PM
Hughes Owen	Chief Executive Officer	Nov 13 '24	Sale	29.95	21,881	655,336	34,979	Nov 13 06:55 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

XOMA

XOMA Royalty Corp

Upgrade your FINVIZ experience